KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Accumulated Expenses (2018 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Accumulated Expenses data on record, last reported at $5.0 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 14.86% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $5.0 million, down 14.86%, while the annual FY2025 figure was $5.0 million, 14.86% down from the prior year.
  • Accumulated Expenses reached $5.0 million in Q4 2025 per AQST's latest filing, down from $5.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $8.7 million in Q4 2021 and bottomed at $3.3 million in Q1 2025.
  • Average Accumulated Expenses over 5 years is $5.9 million, with a median of $5.6 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: surged 370.55% in 2021, then plummeted 39.46% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $8.7 million in 2021, then decreased by 8.8% to $8.0 million in 2022, then dropped by 18.45% to $6.5 million in 2023, then dropped by 9.08% to $5.9 million in 2024, then dropped by 14.86% to $5.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $5.0 million in Q4 2025, $5.1 million in Q3 2025, and $5.0 million in Q2 2025.